EU Confirms Suspension Of 700 Generics But Indian Impact Unclear
This article was originally published in PharmAsia News
An EU order to pull some 700 generic drug products off retail shelves over testing quality issues could cut India’s pharmaceutical annual exports by at least $1 billion, according to a government body, although there is some disagreement over the likely actual impact. The suspension has also fuelled fresh doubts about the standards followed by India's troubled clinical trials industry.
You may also be interested in...
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.
Prime Minister Narendra Modi’s government has decided to "comprehensively review" India's antiquated drug legislation to take into account the latest medical developments and improve safety, amid complaints about poor-quality manufacturing and products.